Location History:
- Bresso, IT (2023)
- Aversa, IT (2021 - 2024)
Company Filing History:
3 out of 5,474 
3 out of 3 
1 out of 6 Years Active: 2021-2025
Title: **Innovator Spotlight: Ali Munaim Yousif**
Introduction
Ali Munaim Yousif is an accomplished inventor based in Aversa, Italy, recognized for his significant contributions to the field of pharmaceutical research. With a total of four patents to his name, Yousif has focused on innovative compounds that target specific receptor activities, advancing the potential treatment options for various diseases.
Latest Patents
Among his notable patents are the "Bicyclic CX3CR1 receptor agonists." These patents disclose novel cycloalka[b]heteroaryl compounds that possess CX3CR1/fractalkine receptor (CX3CR1) agonistic properties. The patents detail pharmaceutical compositions comprising these compounds, alongside the chemical processes necessary for their preparation. The applications of these innovations highlight their use in the treatment or prophylaxis of diseases associated with CX3CR1 receptor activity in animals, particularly humans.
Career Highlights
Ali has garnered valuable experience working with prestigious organizations, including the University of Texas System and Golgi Neurosciences S.r.l. His time at these institutions has not only enriched his expertise but has also facilitated groundbreaking research and development initiatives within the pharmaceutical sector.
Collaborations
Throughout his professional journey, Yousif has collaborated with notable colleagues such as Paolo Pevarello and Russell Thomas. These partnerships have been instrumental in fostering an environment of innovation and shared knowledge, leading to the development of promising therapeutic solutions.
Conclusion
Ali Munaim Yousif stands out as a dedicated inventor, continuously striving to enhance medical treatments through his innovative patents. His work in developing CX3CR1 receptor agonists demonstrates the potent impact of targeted research and collaboration in addressing complex health challenges. As he continues to advance his research, the pharmaceutical community eagerly anticipates the potential breakthroughs that may arise from his future endeavors.